Med Life Sa · BVB:M
Med Life Sa — Q1 2020 Earnings Presentation
17 slides from Med Life Sa's earnings presentation, Jun 23, 2020
Slide 1: Q1 2020 Financial Results
Q1 2020 Financial Results Investors and Analysts presentation 23 June, 2020
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation is not, and nothing in it should be construed as, an offer, invitation or recommendation in respect of Med Life SA’s securities, or an offer, invitation or recommendation to sell, or a solicitation of an offer to buy Med Life SA’s securities. Neither this presentat
Slide 3: Agenda
1 • Q1 2020 at a glance Highlights 2020 • Key messages Q1 2020 AGENDA Financial overview • Consolidated Statement of Profit and Loss 2 • • Consolidated Statement of Financial Position Consolidated Statement of Cash Flow Q&A Session 3 3/
Slide 4: Highlights Q1 2020
Highlights Q1 2020 • Q1 2020 at a glance • Key messages Q1 2020 1 4/
Slide 5: Q1 2020 at a glance (1/5)
Q1 2020 at a glance (1/5) Covid`19 outbreak –unique epidemiological context, an unprecedented crisis The first case of COVID`19 was officially registered on February 26, 2020 The threshold of 100 infected people was exceeded, 139 cases being registered until March 15 The state of emergency was decla
Slide 6: Q1 2020 at a glance (2/5)
Q1 2020 at a glance (2/5) European Commission forecasts for the Romanian economy a drop by 6% in GDP in 2020, after several years of robust growth, while budget deficit to reach 9.2% of GDP RON faced depreciation pressure, but was kept under control by NBR The activity of the Romanian healthcare sys
Slide 7: Q1 2020 at a glance (3/5)
Q1 2020 at a glance (3/5) - Debt moratorium for individuals and companies affected by the crisis (based on declaration for individuals, decrease of 25% of revenues for companies) - grace period up to 9 months (not beyond YE 2020) & interest accrued (capitalized for consumer loans, repaid in 60 equal
Slide 8: Q1 2020 at a glance (4/5)
Q1 2020 at a glance (4/5) Rapid MedLife adaptation, prepared to cope with challenges Integrated business model, with diversified business lines 3 RT- PCR fully equipped laboratories in Bucharest, Sfantu Gheorghe and Timisoara, with a total testing capacity of >1,000 tests per day First study on the
Slide 9: Q1 2020 at a glance (5/5)
Q1 2020 at a glance (5/5) Supporting our clients Launched online medical platform where patients can get in touch by videoconference with doctors from many specialties for consultation, diagnosis and treatment, including psychological counseling; 24/7 Medical Hotline Prevention and Best Practices Gu
Slide 10: Key messages Q1 2020
Key messages Q1 2020 Pro-forma figures Strong Balance Sheet 508m RON Tangible assets with all large hospitals buildings owned by the Group 808m RON Total Non-current assets solid liquidity position 88m RON Cash and cash equivalents operating profit and EBITDA remained stable 18.9m RON operating prof
Slide 11: Financial overview
Financial overview Consolidated Stetement of Profit and Loss Consolidated Statement of Financial Position Consolidated Stetement of Cash Flow 2 11 /
Slide 12: Consolidated Statement of Profit and Loss (1/3)
Consolidated Statement of Profit and Loss (1/3) Q1 2020 Pro-forma vs. Q1 2019 IFRS ❑ Sales increased by 11.0%, to 256.3m RON, like2like growth of 7% ❑ OPEX increased by 9.3%, to 238.3m RON ❑ EBIT increased by 26.1% to 18.9m RON, a margin expansion of 0.9 p.p. to 7.4% (from 6.5%) ❑ EBITDA increased b
Slide 13: Consolidated Statement of Profit and Loss (2/3)
Consolidated Statement of Profit and Loss (2/3) Operational KPIs The increase of 14.3% Q1 2020 vs Q1 2019 (on IFRS) and of 11% Q1 2020 vs Q1 2019 (Pro-forma) is the effect of: ➢ Acquisitions made subsequent to Q1 2019 ➢ strong operating performance in January and February ➢ drop in sales of approx.
Slide 14: Consolidated Statement of Profit and Loss (3/3)
Consolidated Statement of Profit and Loss (3/3) OPEX Evolution 14 / 1.Highlights 2020 2. Financial overview 3. Q&A Session
Slide 15: Consolidated Statement of Financial Position (1/2)
Consolidated Statement of Financial Position (1/2) Net debt to Pro-forma EBITDA ratio 4 3 3.1 3.2 3.3 3.1 2 2.6 2.7 1 0 2015 2016 2017 2018 2019 Q1 2020 15 / 1.Highlights 2020 2. Financial overview 3. Q&A Session
Slide 16: Consolidated Statement of Cash Flow
Consolidated Statement of Cash Flow Financing activities & liquidity side: 1. 14m EUR undrawn facility was converted in working capital Covid`19 facility, out of which 5m EUR were drawn and available in accounts as at March 31, 2020 1. Additional exposure of 20m EUR approved by the Banks for the dev
Slide 17: Q&A Session Thank you!
Q&A Session Thank you! 3 17 /